BR112018070497A2 - métodos e formulações farmacêuticas para tratamento de condições oculares - Google Patents

métodos e formulações farmacêuticas para tratamento de condições oculares

Info

Publication number
BR112018070497A2
BR112018070497A2 BR112018070497A BR112018070497A BR112018070497A2 BR 112018070497 A2 BR112018070497 A2 BR 112018070497A2 BR 112018070497 A BR112018070497 A BR 112018070497A BR 112018070497 A BR112018070497 A BR 112018070497A BR 112018070497 A2 BR112018070497 A2 BR 112018070497A2
Authority
BR
Brazil
Prior art keywords
formulations
eye conditions
treating eye
pharmaceutical methods
methods
Prior art date
Application number
BR112018070497A
Other languages
English (en)
Inventor
Michael Ackermann Douglas
Loudin James
J Mandell Kenneth
Original Assignee
Oyster Point Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc
Publication of BR112018070497A2 publication Critical patent/BR112018070497A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

são descritos métodos e formulações farmacêuticas para tratamento de condições oculares.
BR112018070497A 2016-04-07 2017-04-06 métodos e formulações farmacêuticas para tratamento de condições oculares BR112018070497A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662319648P 2016-04-07 2016-04-07
PCT/US2017/026385 WO2017177024A1 (en) 2016-04-07 2017-04-06 Methods of treating ocular conditions

Publications (1)

Publication Number Publication Date
BR112018070497A2 true BR112018070497A2 (pt) 2019-01-29

Family

ID=58549326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018070497A BR112018070497A2 (pt) 2016-04-07 2017-04-06 métodos e formulações farmacêuticas para tratamento de condições oculares

Country Status (21)

Country Link
US (2) US10709707B2 (pt)
EP (2) EP3439661B1 (pt)
JP (3) JP7090551B2 (pt)
KR (2) KR102485299B1 (pt)
CN (3) CN109310692B (pt)
AU (1) AU2017248276B2 (pt)
BR (1) BR112018070497A2 (pt)
CA (1) CA3020170A1 (pt)
DK (1) DK3439661T3 (pt)
EA (1) EA201892265A1 (pt)
ES (1) ES2893126T3 (pt)
IL (3) IL299204A (pt)
MX (2) MX2018012230A (pt)
MY (1) MY199237A (pt)
NZ (2) NZ785093A (pt)
PH (1) PH12018502154A1 (pt)
PT (1) PT3439661T (pt)
SG (1) SG11201808650QA (pt)
TW (2) TWI790997B (pt)
WO (1) WO2017177024A1 (pt)
ZA (1) ZA201807438B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
FI3848028T3 (fi) 2014-10-20 2024-08-21 Oyster Point Pharma Inc Okulaaristen sairauksien hoitomenetelmiä
PT3439661T (pt) 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares
WO2020014232A1 (en) 2018-07-10 2020-01-16 Oyster Point Pharma, Inc. Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN117355307A (zh) * 2021-05-07 2024-01-05 奥伊斯特普安生物制药公司 载体与烟碱激动剂的协同疗法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en) 2001-07-09 2003-01-09 Pfizer Inc. Pharmaceutical composition and method of modulating cholinergic function in a mammal
BR0214559A (pt) 2001-11-29 2007-03-13 Pfizer Prod Inc sais de ácido succìnico do 5,8,14-triazatetraciclo [10.3.1.0<2,11>.0<4,9>]-hexadeca-2(11),3,5,7,9-penteno e suas composições farmacêuticas
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en) 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
EP1885332A2 (en) 2005-03-22 2008-02-13 NicoNovum AB Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
TWI454262B (zh) 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
BRPI0808634A2 (pt) 2007-02-02 2014-08-05 Pfizer Prod Inc Compostos tricíclicos, composições e métodos.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
US20090093446A1 (en) 2007-10-05 2009-04-09 Winston Laboratories, Inc. Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
RU2010140613A (ru) 2008-03-05 2012-04-10 Таргасепт, Инк. (Us) Амиды диазабициклоалканов, селективные в отношении подтипа никотиновых ацетилхолиновых рецепторов
WO2010028011A1 (en) 2008-09-05 2010-03-11 Targacept, Inc. Amides of diazabicyclononanes and uses thereof
CN102143963A (zh) 2008-09-05 2011-08-03 塔加西普特公司 二氮杂双环辛烷的酰胺及其应用
KR20110091501A (ko) * 2008-10-14 2011-08-11 싸이코제닉스 아이엔씨. 니코틴성 아세틸콜린 수용체 리간드 및 이들의 용도
US9145396B2 (en) * 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en) 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
NZ611965A (en) 2008-12-01 2015-01-30 Targacept Inc Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
NZ596734A (en) * 2009-06-17 2014-02-28 Targacept Inc Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
MX2014004621A (es) 2011-10-20 2014-08-22 Novartis Ag Biomarcadores predictivos de la capacidad de respuesta al receptor de acetil-colina nicotinico alfa-7.
EP3029463A1 (en) 2011-11-30 2016-06-08 DiagnosTear Ltd Dry eye diagnostic
FI3848028T3 (fi) * 2014-10-20 2024-08-21 Oyster Point Pharma Inc Okulaaristen sairauksien hoitomenetelmiä
PT3439661T (pt) 2016-04-07 2021-09-30 Oyster Point Pharma Inc Métodos de tratamento de condições oculares

Also Published As

Publication number Publication date
TW201737917A (zh) 2017-11-01
US20190201397A1 (en) 2019-07-04
NZ785093A (en) 2024-07-05
PH12018502154A1 (en) 2019-07-08
US10709707B2 (en) 2020-07-14
ES2893126T3 (es) 2022-02-08
MX2021010399A (es) 2022-01-18
EP3970724A1 (en) 2022-03-23
NZ746468A (en) 2023-06-30
IL290069A (en) 2022-03-01
WO2017177024A1 (en) 2017-10-12
CN114533737B (zh) 2024-05-31
EP3439661A1 (en) 2019-02-13
AU2017248276A1 (en) 2018-11-22
PT3439661T (pt) 2021-09-30
TWI790997B (zh) 2023-02-01
SG11201808650QA (en) 2018-10-30
CN109310692A (zh) 2019-02-05
IL262102B (en) 2022-03-01
IL290069B2 (en) 2023-05-01
EA201892265A1 (ru) 2019-04-30
JP2024103594A (ja) 2024-08-01
JP2019513759A (ja) 2019-05-30
DK3439661T3 (da) 2021-10-18
ES2893126T8 (es) 2022-05-23
JP2022120125A (ja) 2022-08-17
CA3020170A1 (en) 2017-10-12
MX2018012230A (es) 2019-03-28
WO2017177024A8 (en) 2018-11-08
EP3439661B1 (en) 2021-08-04
AU2017248276B2 (en) 2023-07-13
IL290069B1 (en) 2023-01-01
KR102512777B1 (ko) 2023-03-23
IL262102A (en) 2018-11-29
IL299204A (en) 2023-02-01
TW202320785A (zh) 2023-06-01
CN114533737A (zh) 2022-05-27
KR102485299B1 (ko) 2023-01-06
ZA201807438B (en) 2024-09-25
KR20230010813A (ko) 2023-01-19
CN114432313A (zh) 2022-05-06
KR20190005859A (ko) 2019-01-16
CN109310692B (zh) 2022-01-25
JP7090551B2 (ja) 2022-06-24
US20200345734A1 (en) 2020-11-05
MY199237A (en) 2023-10-22

Similar Documents

Publication Publication Date Title
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
BR112019012343A2 (pt) anticorpos il-11ra
GB2541571A (en) Pharmaceutical compositions
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112018012304A2 (pt) composições e métodos para diminuir expressão de tau
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
BR112018005331A2 (pt) inibidores de pcna
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
TR201901228T4 (tr) Vortioksetin piroglutamat.
PH12017500602A1 (en) Methods for treating ocular conditions
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017001888A2 (pt) formulações biológicas para instilação intravesical

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25G Requested change of headquarter approved

Owner name: OYSTER POINT PHARMA, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2775 DE 12/03/2024 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]